Second Primary Malignancy in Patients with Hypopharyngeal Carcinoma: A SEER-Based Study

Guo, Liqing; Fu, Yanpeng; Chen, Miao; Wu, Shuhong; Zhu, Yaqiong; Liu, Yuehui

doi:10.2147/ijgm.s339595

Cited by 5 publications

(11 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…From a total of 829 articles obtained after deleting duplicates, 703 were excluded based on title and abstract and 126 after reading the full text (Figure 1 ). Finally, 38 articles were included in this systematic review: 36 cohort studies (Adams et al, 2019 ; Adjei Boakye et al, 2019 ; Arie et al, 2021 ; Bertolini et al, 2021 ; Bosshart et al, 2021 ; Bugter et al, 2021 ; Bukovszky et al, 2022 ; Cadoni et al, 2017 ; Chow et al, 2019 ; Feng et al, 2017 ; Guo et al, 2021 ; Harada et al, 2017 ; Ho et al, 2022 ; Hosokawa et al, 2018 ; Inoue et al, 2021 ; Iwatsubo et al, 2019 ; León et al, 2020 ; Leoncini et al, 2018 ; Li et al, 2020 ; Lin et al, 2020 ; Liu et al, 2017 ; Martel et al, 2017 ; Milliet et al, 2021 ; Min et al, 2019 ; Nishimura et al, 2021 ; Overwater et al, 2022 ; Petersen et al, 2022 ; Piersiala et al, 2020 ; Sawaf et al, 2022 ; Stepan et al, 2022 ; Su et al, 2019 ; Su et al, 2020 ; Tseng et al, 2017 ; Wang et al, 2017 ; Wang et al, 2019 ; Zhang et al, 2019 ) and 2 case‐control studies (Ni et al, 2018 ; Watanabe et al, 2017 ).…”

Section: Resultsmentioning

confidence: 99%

“…In addition, they found that having a marital status different to married also decreased the risk. However, Guo et al ( 2021 ) found that to be unmarried increased the risk of a SPT. Lastly, two studies evaluated race and found an increase risk among black people compared to white (Adjei Boakye et al, 2019 ; Li et al, 2020 ).…”

Section: Resultsmentioning

confidence: 99%

“…Twenty‐eight studies measured some parameters related to extension of the primary tumour (stage, size, lymph node involvement, metastasis or invasion), and 12 of them found an association with the appearance of SPTs. Except for Feng et al, Li et al, Adjei Boakye et al and Petersen et al (Adjei Boakye et al, 2019 ; Feng et al, 2017 ; Li et al, 2020 ; Petersen et al, 2022 ), the rest of the articles showed that the higher the extension of the index tumour, the higher the risk (Cadoni et al, 2017 ; Guo et al, 2021 ; Ho et al, 2022 ; Lin et al, 2020 ; Ni et al, 2018 ; Wang et al, 2017 ; Wang et al, 2019 ; Zhang et al, 2019 ).…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Factors associated with the development of second primary tumours in head and neck cancer patients

Salcedo‐Bellido

Requena

Mateos

et al. 2022

European J Cancer Care

View full text Add to dashboard Cite

Introduction:The development of second primary tumours (SPTs) is one of the main causes of low survival in patients with head and neck cancer (HNC). The aim of this study was to review the evidence about factors associated with developing SPTs in patients with HNC.Methods: An updated systematic review was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines, and the search was performed in Pubmed and Scopus. Only original articles with a cohort or casecontrol design were included. Article quality was assessed with the Newcastle-Ottawa scale.Results: Thirty-six and two case-control studies were included, with quality medium (n = 5) to high (n = 33). Tobacco showed a significant association with SPT development, with risks ranging from 1.41 (95%CI: 1.04-1.91) to 5.52 (95%CI: 2.91-10.49).Regarding alcohol, risks ranged from 1.46 (95%CI: 1.12-1.91) to 21.3 (95%CI: 2.9-156). Location of the index tumour in the hypopharynx/oropharynx, absence of human papillomavirus and presence of a premalignant lesion also increased the risk of SPTs. More controversy was found for sex, age and other clinical factors of the tumour. Conclusion:Toxic lifestyle habits and clinical factors were associated with the risk of SPTs in HNC patients. These findings may improve individualised prevention strategies in its follow-up.head and neck cancer, second primary tumours | INTRODUCTIONHead and neck cancer (HNC) has a significant burden worldwide. This heterogeneous group of tumours (including lip, oral cavity, larynx and pharynx) occupies the eighth position in incidence worldwide, with 858,348 new cases in 2020, that is up to 4.6% of all cancers (Sung et al., 2021). Last trends indicate an expected incidence increase in most of the HNC tumours (Aupérin, 2020;Simard et al., 2014).

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Factors associated with the development of second primary tumours in head and neck cancer patients

Salcedo‐Bellido

Requena

Mateos

et al. 2022

European J Cancer Care

View full text Add to dashboard Cite

show abstract

“…Our proposed model focuses on pediatric cancer patient survivors, to propose a causative link between acute thymic involution and defective cancer immunoediting mechanisms leading to SPMs. Nevertheless, SPM development also occurs in non-pediatric patients, and similar mechanisms could also be relevant in these populations (41,(213)(214)(215)(216)(217)(218)(219)(220)(221). The pediatric cancer survivor paradigm was easier to discuss in our model, first because there are long-term follow-up epidemiological data that can be used as a better proof-of-concept (222-224), and second, because thymic functions are relatively stronger in childhood, as compared to other ages (201).…”

Section: Criticisms Of the Proposed Model And Future Repercussionsmentioning

confidence: 99%

A Proposed Link Between Acute Thymic Involution and Late Adverse Effects of Chemotherapy

Lagou

Anastasiadou²,

Karagiannis³

2022

Front. Immunol.

View full text Add to dashboard Cite

Epidemiologic data suggest that cancer survivors tend to develop a protuberant number of adverse late effects, including second primary malignancies (SPM), as a result of cytotoxic chemotherapy. Besides the genotoxic potential of these drugs that directly inflict mutational burden on genomic DNA, the precise mechanisms contributing to SPM development are poorly understood. Cancer is nowadays perceived as a complex process that goes beyond the concept of genetic disease and includes tumor cell interactions with complex stromal and immune cell microenvironments. The cancer immunoediting theory offers an explanation for the development of nascent neoplastic cells. Briefly, the theory suggests that newly emerging tumor cells are mostly eliminated by an effective tissue immunosurveillance, but certain tumor variants may occasionally escape innate and adaptive mechanisms of immunological destruction, entering an equilibrium phase, where immunologic tumor cell death “equals” new tumor cell birth. Subsequent microenvironmental pressures and accumulation of helpful mutations in certain variants may lead to escape from the equilibrium phase, and eventually cause an overt neoplasm. Cancer immunoediting functions as a dedicated sentinel under the auspice of a highly competent immune system. This perspective offers the fresh insight that chemotherapy-induced thymic involution, which is characterized by the extensive obliteration of the sensitive thymic epithelial cell (TEC) compartment, can cause long-term defects in thymopoiesis and in establishment of diverse T cell receptor repertoires and peripheral T cell pools of cancer survivors. Such delayed recovery of T cell adaptive immunity may result in prolonged hijacking of the cancer immunoediting mechanisms, and lead to development of persistent and mortal infections, inflammatory disorders, organ-specific autoimmunity lesions, and SPMs. Acknowledging that chemotherapy-induced thymic involution is a potential risk factor for the emergence of SPM demarcates new avenues for the rationalized development of pharmacologic interventions to promote thymic regeneration in patients receiving cytoreductive chemotherapies.

show abstract

“…Previous studies have reported several potential risk predictors for SPM such as smoking, alcohol consumption and chemotherapy 8‐10 . IP‐HNSCC survivors with localized diseases are more vulnerable to developing SPM than those with distant diseases 10 .…”

Section: Introductionmentioning

confidence: 99%

Time‐varying association of second primary malignancy and long‐term survival outcomes in patients with head and neck cancer

Zhu

Heng

Zhou

et al. 2023

Intl Journal of Cancer

View full text Add to dashboard Cite

A high risk of developing second primary malignancy (SPM) has been reported among head and neck cancer patients. Here, we aimed to statistically quantify the impact of SPM development on the survival of head and neck cancer patients. Our study was conducted using the Surveillance, Epidemiology and End Results database to collect the data of 48 316 patients who received curative surgical resection for initial primary head and neck squamous cell carcinoma (IP-HNSCC) in 1975 to 2019. SPM diagnosis was treated as a time-varying covariate and multivariable Cox regression analysis was conducted to estimate the association between SPM development and survival, overall or by the subsite of IP-HNSCC. Of the included patients, 11 238 patients (23.3%) developed SPM during the follow-up period. A significant reduction in survival was observed among patients with SPM (hazard ratio [HR] for overall survival, 3.30; 95% confidence interval [CI]: 3.20-3.41). The impact of SPM development on reduced survival was more significant in patients with localized IP-HNSCC vs regional IP-

show abstract

Second Primary Malignancy in Patients with Hypopharyngeal Carcinoma: A SEER-Based Study

Cited by 5 publications

References 39 publications

Factors associated with the development of second primary tumours in head and neck cancer patients

Factors associated with the development of second primary tumours in head and neck cancer patients

A Proposed Link Between Acute Thymic Involution and Late Adverse Effects of Chemotherapy

Time‐varying association of second primary malignancy and long‐term survival outcomes in patients with head and neck cancer

Contact Info

Product

Resources

About